The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: A placebo-controlled trial

Current Therapeutic Research - Clinical and Experimental

Volumn 60, Issue 12, 1999, Pages 650-660

  Muirhead, Norman ^a,f   Feagan, Brian F ^a   Mahon, Jeffrey ^a   Lewanczuk, Richard Z ^b   Rodger, N Wilson ^c   Botteri, Florence ^d   Oddou Stock, Pascale ^d   Pecher, Eckhard ^d   Cheung, Raphael ^e  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c St Joseph Health Center   (Canada)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Hotel Dieu Grace Hospital Windsor   (Canada)

^f LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Albumin excretion rate; Microalbuminuria; Type 2 diabetes mellitus; Valsartan

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; PLACEBO; VALSARTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL;

EID: 0033451175     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(99)90003-6     Document Type: Article

References (18)

1. 1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
2. 2. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA. 1994;271:275-279.
3. 3. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118:577-581.
4. 4. Stornello M, Valvo EV, Scapellato L. Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: Comparative effects of angiotensin-converting enzyme inhibitors and β-adrenoceptor blockers. Clin Sci. 1992;82:19-23.
5. 5. Mathiesen ER, Hommel E, Hansen HP, et al. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J. 1999;319:24-25.
6. 6. Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin converting enzyme inhibitor-associated angioedema. JAMA. 1997;278:232-233.
7. 7. Zhuo J, Alcorn D, Harris PJ, Mendelsohn FA. Localization and properties of angiotensin II receptors in rat kidney. Kidney Int Suppl. 1993;42:S40-S46.
8. 8. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1992;90:766-771.
9. 9. Pollock DM, Divish BJ, Polakowski JS, Opgenorth TJ. Angiotensin II receptor blockade improves renal function in rats with reduced renal mass. J Pharmacol Exp Ther. 1993; 267:657-663.
10. 10. Nielsen S, Dollerup J, Nielsen B, et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 month study. Nephrol Dial Transplant. 1997;12(Suppl2):19-23.
11. 11. Mattock MB, Morrish NJ, Viberti V, et al. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes. 1992;41:736-741.
12. 12. Mogensen CE. Prevention and treatment of renal disease in insulin-dependent diabetes mellitus. Semin Nephrol. 1990;10:260-273.
13. 13. Bennett P. Microalbuminuria and diabetes: A critique assessment of urinary albumin excretion and its role in screening for diabetic nephropathy. Am J Kidney Dis. 1989;13: 29-34.
14. 14. Romero R, Salinas I, Lucas A, et al. Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors. Diabetes Care. 1993;16:597-600.
15. 15. Abbott KC, Sanders LR, Bakris GL. Microalbuminuria in non-insulin dependent diabetes mellitus. Arch Intern Med. 1994;154:146-153.
16. 16. Dominguez LJ, Barbagallo M, Kattah W, et al. Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects. Am J Hypertens. 1995;8: 808-814.
17. 17. Garcia DL, Rennke HG, Brenner BM, Anderson S. Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation. J Clin Invest. 1987;80:867-874.
18. 18. Morelli E, Loon N, Meyer T, et al. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes. 1990;39:2-8.